Company intelligence / Profile preview

Bsense Bio Therapeutics

Ness Ziona, Shfella Area, Israelbsense-bio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has generated preclinical proof-of-concept in several chronic pain models and Tinnitus. Their lead compound BSEN627 has shown positive topline data in comparative preclinical studies, significantly alleviating chronic pain without major side effects[7].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

BSEN760

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Bsense Bio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bsense Bio Therapeutics.

Explore the full profile